Kurreck, A.
Geissler, M.
Martens, U. M.
Riera-Knorrenschild, J.
Greeve, J.
Florschütz, A.
Wessendorf, S.
Ettrich, T.
Kanzler, S.
Nörenberg, D.
Seidensticker, M.
Held, S.
Buechner-Steudel, P.
Atzpodien, J.
Heinemann, V.
Stintzing, S.
Seufferlein, T.
Tannapfel, A.
Reinacher-Schick, A. C.
Modest, D. P. http://orcid.org/0000-0002-6853-0599
Funding for this research was provided by:
AIO-Studien gGmbH
Article History
Received: 15 April 2020
Accepted: 12 May 2020
First Online: 24 May 2020
Compliance with ethical standards
:
: Annika Kurreck—travel, accommodation, and expenses: Roche and Medac. Michael Geissler—consulting or advisory role: Amgen, Lilly, and Merck. Serono—travel, accommodation, and expenses: Amgen. Uwe M. Martens—consulting or advisory role: Merck Sharp & Dohme Oncology, Roche, Bristol-Myers Squibb, and Celgene; travel, accommodation, and expenses: Amgen, Bristol-Myers Squibb, and Celgene. Jorge Riera-Knorrenschild—consulting or advisory role: Boehringer Ingelheim, Pierre Fabre, and Novartis; travel, travel, accommodations, and expenses: Amgen. Jobst Greeve—no conflicts of interest. Axel Florschütz—Honoraria: Janssen; consulting or advisory role: Servier and Roche; travel, accommodations, and expenses: Janssen. Swen Wessendorf—no conflicts of interest. Thomas Ettrich—consulting or advisory role: Merck Serono, Sanofi, Bayer HealthCare Pharmaceuticals, Merck Serono, Bristol-Myers Squibb, Pfizer, Novartis, Roche, and Lilly; Speakers’ Bureau: Sanofi, Celgene, Bristol-Myers Squibb, and Baxalta/Shire; travel, accommodations, expenses: Ipsen. Stephan Kanzler—no conflicts of interest. Dominik Nörenberg—employment: Smart Reporting GmbH. Max Seidensticker—Honoraria: Bayer HealthCare Pharmaceuticals, Sirtex Medical, Cook Medical, BTG, and Siemens Healthineers; research funding: Sirtex Medical (Inst) and Bayer HealthCare Pharmaceuticals (Inst); travel, accommodations, and expenses: Boston Scientific. Swantje Held—no conflicts of interest. Petra Buechner-Steudel—no conflicts of interest. Jens Atzpodien—no conflicts of interest. Volker Heinemann—Honoraria: Roche, Celgene, Amgen, Sanofi, Merck, Sirtex Medical, Baxalta, Lilly, Boehringer Ingelheim, Taiho Pharmaceutical, and Servier; consulting or advisory role: Merck, Amgen, Roche, Sanofi, Boehringer Ingelheim, Celgene, Sirtex Medical, Baxalta, Servier, Halozyme, Merck Sharp & Dohme, Bristol-Myers Squibb, Merck Sharp, and Dohme Oncology; research funding: Merck (Inst), Amgen (Inst), Roche (Inst), Celgene (Inst), Boehringer Ingelheim (Inst), Sirtex Medical (Inst), Shire (Inst), and Servier (Inst); travel, accommodations, and expenses: Merck, Roche, Sirtex Medical, Amgen, Servier, Shire, Merck Sharp & Dohme, and Bristol-Myers Squibb. Sebastian Stintzing—Honoraria: Merck, Roche, Amgen, Bayer, Sanofi, Sirtex Medical, and Eli Lilly; consulting or advisory role: Merck, Roche, Sanofi, Bayer, Amgen, Boehringer Ingelheim, Eli Lilly, and Takeda; travel, accommodations, expenses: Merck, Roche, Sanofi, Bayer, Sirtex Medical, Amgen, Eli Lilly, and Takeda. Thomas Seufferlein—Honoraria: Sanofi, Falk Foundation, Roche, Celgene, Merck Serono, Bayer Schering Pharma, Amgen, Halozyme, Servier, and Baxalta; consulting or advisory role: Merck Serono, Celgene, Bayer HealthCare Pharmaceuticals, Shire, Baxalta, Halozyme, and Roche/Genentech; research funding: Celgene and Sanofi; travel, accommodations, and expenses: Sanofi, Roche, Celgene, Merck Serono, and Servier. Andrea Tannapfel—Honoraria: Falk Foundation, Merck, Amgen, Pfizer, and Med Update; other: Pathohistologic testimonials for insurances. Anke C. Reinacher-Schick—Honoraria: Amgen, Roche, Pfizer, Sanofi, Merck Serono, Shire, Celgene, Lilly, Bristol-Myers Squibb, Servier, Baxalta, Merck Sharp & Dohme, Aurikamed, Bonita Pharmaceuticals, Iomedico, MCI (managing meetings in cancer care and education), Med Publico, and Promedicis; consulting or advisory role: Amgen, Roche, Pfizer, Sanofi, Merck Serono, Celgene, Bristol-Myers Squibb, Servier, Baxalta, Merck Sharp & Dohme, and Onkowissen; research funding: Roche (Inst), Celgene (Inst), Ipsen (Inst), Amgen (Inst), Alexion (Inst), AstraZeneca (Inst), Lilly (Inst), Servier (Inst), Arbeitsgemeinschaft Internistische Onkologie Studien (Inst), Agricola (Inst), PPD Global Limited, UK (Inst), Mologen Berlin (Inst), Universität München (Inst), Universität Erlangen (Inst), Universität Köln (Inst), Pharma Consulting Group Schweden (Inst), and Syneed Medidata (Inst); travel, accommodations, and expenses: Ipsen, Amgen, Celgene, Onkowissen, Roche, and Servier. Dominik Paul Modest—Honoraria: Merck Serono, Amgen, Roche, Servier, Bristol-Myers Squibb, Pfizer, Taiho Pharmaceutical, and Merck Sharp & Dohme; consulting or advisory role: Merck Serono, Amgen, Merck Sharp & Dohme, Roche, Servier, and Bristol-Myers Squibb; research funding: Merck Serono (Inst), Roche (Inst), and Amgen (Inst); travel, accommodations, and expenses: Amgen, Merck Serono, Bayer HealthCare Pharmaceuticals, Servier, Bristol-Myers Squibb, and Roche.
: Informed consent was obtained from all individual participants included in the underlying VOLFI-trial.
: The authors affirm that human research participants provided informed consent for the publication of the data obtained within the underlying VOLFI-trial.
: The datasets analyzed are available from the corresponding author on reasonable request.